Frank Fekete is a Managing Director at Centerview on the healthcare team in the New York office. He has over a decade of experience providing advice to boards and senior management teams regarding strategic initiatives including mergers and acquisitions, private and public financings, and other corporate processes totaling more than $75 billion in value across developed and emerging markets. Select recent M&A experience includes: Merck’s $11.5bn acquisition of Acceleron, Cerevel’s $8.7bn sale to AbbVie, Chinook’s sale to Novartis for up to $3.5bn, Viela’s sale to Horizon Therapeutics for $3.1bn, EyeBio’s sale to Merck for up to $3.0bn, Boston Pharma’s sale to GSK for up to $2.0bn and Ambrx’s sale to JnJ for $2.0bn. Select recent China M&A includes: Gracell’s sale to AstraZeneca, Proteologix’s sale to JNJ, Curon’s CD3xCD19 asset sale to Merck, and Lian Bio’s sale of Mavacamten rights to Bristol Myers. Additionally, Frank has advised on some of the largest financings in the industry raising capital for innovative biopharmas including: Allogene, Cerevel, Intellia, Juno, Sana, SpringWorks and uniQure. Prior to joining Centerview, Frank was a Vice President at Goldman Sachs in the Healthcare group. He received an M.S. in Physiology and Biophysics from Georgetown’s School of Medicine and a B.A. from Villanova University’s Honors College. He lives in New Jersey with his wife, daughter and labrador retriever.